CN Bio PhysioMimix® Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing. CN Bio, a
OBN Awards 2023 winner!
CN Bio wins ‘Most Impactful Industry Collaboration of the Year’ at the OBN Awards 2023 for ongoing research with the FDA Six-year collaboration
CN Bio appoints Neil Rumbelow as Director of Product Development
Key senior appointment to drive research and development activities for portfolio of PhysioMimix OOC microphysiological systems CN Bio, a
CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems
Partnership to provide customers with direct access to portfolio of highly characterized hepatic cells to recreate advanced Liver-on-a-Chip
CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer
Cambridge, UK, 30th August 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ
CN Bio appoints Dr. Samantha Macro as Chief Financial Officer
Cambridge, UK, 06 June 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological
CN Bio appoints Deepak Singh as Vice President of Sales and Marketing
Cambridge, UK, 14 March 2023: CN Bio, a leading Organ-on-a-chip (OOC) company that designs and manufactures single-and multi-organ microphysiological
CN Bio extends microphysiological system portfolio with PhysioMimix Single-Organ Higher Throughput System
Cambridge, UK, CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS),
The FDA further expands collaboration with CN Bio to evaluate the PhysioMimix Multi-organ microphysiological system
Cambridge, UK, 17th January 2023: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single-and multi-organ